Because of HDAC inhibitors ability to affect multiple pathways and genes involved in apoptosis [25], cell cycle arrest [26] and angiogenesis [24], [27], [28], their greatest potential as targeted therapies maybe to be utilized in novel combinational therapeutic strategies in PCa with already existing chemotherapies such as docetaxel [29], or with other novel targeted chemotherapies including mTOR inhibitors [19]. Here, HDAC9 is linked to posterior cortical atrophy.